Antiviral Effects of Anti-HBs Immunoglobulin and Vaccine on HBs Antigen Seroclearance for Chronic Hepatitis B Infection

Overview

Journal J Gastroenterol

Specialty Gastroenterology

Date 2016 Mar 5

PMID 26943168

Citations 11

Authors

Masataka Tsuge

Nobuhiko Hiraga

Takuro Uchida

Hiromi Kan

Eisuke Miyaki

Keiichi Masaki

Atsushi Ono

Takashi Nakahara

Hiromi Abe-Chayama

Yizhou Zhang

Makokha Grace Naswa

Tomokazu Kawaoka

Daiki Miki

Michio Imamura

Yoshiiku Kawakami

Hiroshi Aikata

Hidenori Ochi

C Nelson Hayes

Kazuaki Chayama

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Interferon and nucleotide/nucleoside analogues are the main treatments for chronic hepatitis B. These drugs effectively reduce serum hepatitis B virus (HBV) DNA titers but fail to sufficiently reduce hepatitis B surface antigen (HBsAg) levels. Following the recent identification of sodium taurocholate cotransporting polypeptide as a receptor for HBV entry, inhibition of HBV entry has become an attractive therapeutic target for chronic hepatitis B treatment. We therefore evaluated the antiviral effects of antibody to HBsAg (anti-HBs) immunoglobulin (HBIG), which can inhibit HBV entry, by in an vivo study and a clinical trial.

Methods: In the in vivo study, HBV-infected mice were generated from human hepatocyte chimeric mice and treated with HBIG. A clinical trial evaluating HBIG therapy in patients was also performed.

Results: In the mouse study, HBV DNA titers were reduced and serum HBsAg titers decreased to undetectable levels following high-dose HBIG injection. On the basis of this result, eight chronic hepatitis B patients, who had received long-term nucleotide analogue treatment, were treated with monthly HBIG injections as an additional treatment. After 1 year of treatment, an HBsAg level reduction of more than 1 log IU/mL was observed in four patients, and three patients became anti-HBs positive. No adverse events occurred during HBIG therapy.

Conclusion: These results suggest that monthly HBIG injection might benefit patients with chronic hepatitis B whose HBsAg titer becomes lower following long-term nucleotide/nucleoside analogue treatment.

Citing Articles

A therapeutic HBV vaccine containing a checkpoint modifier enhances CD8+ T cell and antiviral responses.

Hasanpourghadi M, Novikov M, Ambrose R, Chekaoui A, Newman D, Xiang Z JCI Insight. 2024; 9(21).

PMID: 39226106 PMC: 11601613. DOI: 10.1172/jci.insight.181067.

Monoclonal antibody applications in travel medicine.

de Jong H, Grobusch M Trop Dis Travel Med Vaccines. 2024; 10(1):2.

PMID: 38221606 PMC: 10789029. DOI: 10.1186/s40794-023-00212-x.

Hepatitis B immunoglobulin inhibits the secretion of HBV via antigen-antibody precipitation in the multivesicular body.

Yoon K, Seo S, Lee K, Oh S, Park M, Hong S Am J Transl Res. 2023; 15(9):5908-5920.

PMID: 37854220 PMC: 10579012.

Development of a highly potent anti-HBs monoclonal antibody for HBV and HDV therapy: An improvement with unsettled questions.

Mouzannar K, Liang T J Hepatol. 2023; 79(5):1079-1081.

PMID: 37586647 PMC: 11653528. DOI: 10.1016/j.jhep.2023.08.002.

Hepatitis B functional cure and immune response.

Zheng J, Wang Z, Feng B Front Immunol. 2022; 13:1075916.

PMID: 36466821 PMC: 9714500. DOI: 10.3389/fimmu.2022.1075916.

References

Lee Y, Suh D, Lim Y, Jung S, Kim K, Lee H . Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006; 43(6):1385-91. DOI: 10.1002/hep.21189. View

Bruix J, Llovet J . Hepatitis B virus and hepatocellular carcinoma. J Hepatol. 2004; 39 Suppl 1:S59-63. DOI: 10.1016/s0168-8278(03)00140-5. View

REED W, Eddleston A, Cullens H, Williams R, Zuckerman A, PETERS D . Infusion of hepatitis-B antibody in antigen-positive active chronic hepatitis. Lancet. 1973; 2(7842):1347-51. DOI: 10.1016/s0140-6736(73)93321-7. View

Piccolo P, Lenci I, Demelia L, Bandiera F, Piras M, Antonucci G . A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther. 2009; 14(8):1165-74. DOI: 10.3851/IMP1466. View

Conjeevaram H, Lok A . Management of chronic hepatitis B. J Hepatol. 2003; 38 Suppl 1:S90-103. DOI: 10.1016/s0168-8278(02)00431-2. View

McALEER W, BUYNAK E, Maigetter R, WAMPLER D, MILLER W, HILLEMAN M . Human hepatitis B vaccine from recombinant yeast. Nature. 1984; 307(5947):178-80. DOI: 10.1038/307178a0. View

Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M . Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A. 2009; 106(47):19975-9. PMC: 2775998. DOI: 10.1073/pnas.0908365106. View

Iwarson S, Tabor E, Thomas H, Goodall A, Waters J, Snoy P . Neutralization of hepatitis B virus infectivity by a murine monoclonal antibody: an experimental study in the chimpanzee. J Med Virol. 1985; 16(1):89-96. DOI: 10.1002/jmv.1890160112. View

SZMUNESS W, Prince A, Goodman M, EHRICH C, Pick R, Ansari M . Hepatitis B immune serum globulin in prevention of nonparenterally transmitted hepatitis B. N Engl J Med. 1974; 290(13):701-6. DOI: 10.1056/NEJM197403282901302. View

10.

Ogata N, Ostberg L, Ehrlich P, Wong D, Miller R, Purcell R . Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci U S A. 1993; 90(7):3014-8. PMC: 46227. DOI: 10.1073/pnas.90.7.3014. View

11.

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z . Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012; 1:e00049. PMC: 3485615. DOI: 10.7554/eLife.00049. View

12.

Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P . Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol. 2011; 26(10):1527-35. DOI: 10.1111/j.1440-1746.2011.06766.x. View

13.

Zoutendijk R, Reijnders J, Brown A, Zoulim F, Mutimer D, Deterding K . Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011; 54(2):443-51. DOI: 10.1002/hep.24406. View

14.

Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T . IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012; 122(2):529-37. PMC: 3266786. DOI: 10.1172/JCI58847. View

15.

Celis E, Abraham K, Miller R . Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology. 1987; 7(3):563-8. DOI: 10.1002/hep.1840070324. View

16.

Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S . Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol. 1999; 30(5):743-8. DOI: 10.1016/s0168-8278(99)80123-8. View

17.

Gish R, Chang T, Lai C, De Man R, Gadano A, Poordad F . Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2009; 17(1):16-22. DOI: 10.1111/j.1365-2893.2009.01146.x. View

18.

Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von Weizsacker F . Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol. 2008; 26(3):335-41. DOI: 10.1038/nbt1389. View

19.

Ni Y, Lempp F, Mehrle S, Nkongolo S, Kaufman C, Falth M . Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2013; 146(4):1070-83. DOI: 10.1053/j.gastro.2013.12.024. View

20.

Murakami Y, Saigo K, Takashima H, Minami M, Okanoue T, Brechot C . Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut. 2005; 54(8):1162-8. PMC: 1774867. DOI: 10.1136/gut.2004.054452. View